Why the study?
Does irbesartan increase plasma atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension?
Does irbesartan increase plasma atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension?
Irbesartan increases plasma ANP levels in patients with moderate essential hypertension, suggesting a potential mechanism contributing to its antihypertensive effects.
May support ANP as a contributor to irbesartan’s effects in hypertension; leaves open causality and generalizability pending randomized confirmation.
The aim of this study was to evaluate the medium-term effects of the selective AT1-blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.7% despite the drop in blood pressure and the slight decrease of atrial and ventricular diameters. These findings indicate that AT,-blockers like irbesartan exert part of their antihypertensive action by increasing ANP plasma levels.
No takes yet. Share an insight, caveat, or question.
Kotridis et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: